Novolog Pharm-Up 1966 vs McKesson: Fair Value & Quality
Both stocks run through our valuation models. Here is how Novolog Pharm-Up 1966 (NVLG) and McKesson (MCK) compare, as of Aug 10, 2026.
As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Novolog Pharm-Up 1966 trades at ILS 0.67 versus a fair value of ILS 0.23 (-66%), while McKesson trades at $870 versus $819 (-6%).
Novolog Pharm-Up 1966
NVLG.TA · ILS · Health Care
-66%
upside to fair value
overvalued
PriceILS 0.67
Fair ValueILS 0.23
Quality43/100
McKesson
MCK · USD · Health Care
-6%
upside to fair value
fairly valued
Price$870
Fair Value$819
Quality66/100
Head-to-head numbers
Green value = the better side for that row (for valuation multiples: lower = cheaper).
Novolog Pharm-Up 1966McKesson
Valuation
66.8×P/E (TTM)21.0×
0.06×P/S (TTM)0.23×
0.31×P/B—
—EV/EBITDA13.9×
—PEG1.57×
0.1%Dividend yield0.4%
ILS 0.04Dividend per share$3.17
Profitability
0%Net margin1%
1%Operating margin2%
1%Return on equity—
1%Return on assets5%
Growth
-0%Revenue growth (YoY)6%
6.2%Avg. growth/yr (3Y)13.4%
9.8%Avg. growth/yr (5Y)11.1%
Balance & size
$112MMarket cap$94B
expensiveGrowth qualityhealthy
McKesson leads: 1 to 8 metric wins.
Dash = not meaningfully computable, for example with negative equity.
Quality in detail
The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.
Novolog Pharm-Up 1966of which business quality 41 · market factors 29McKessonof which business quality 65 · market factors 63
ProfitabilityMargins and returns on capital today
25
49
Quality GrowthAre margins and returns improving?
40
65
CashflowEarnings quality: real cash, not paper profit
InvestmentDisciplined investing over empire-building
100
76
Low VolatilityCalm price path (market factor)
78
83
MomentumPrice trend over the last 3–12 months (market factor)
10
51
52W MomentumDistance to the 52-week high (market factor)
7
62
Net IssuanceBuybacks instead of dilution
83
100
What the models say
The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.
Novolog Pharm-Up 1966
DCF ModelsILS 2.16
Earnings-BasedILS 0.16
Dividend DiscountILS 0.53
MultiplesILS 0.55
Asset-BasedILS 0.47
Economic ProfitILS 0.54
Growth EarningsILS 0.14
13 of 17 models see the stock below the current price.
McKesson
DCF Models$955
Earnings-Based$444
Dividend Discount$57.26
Multiples$848
Growth DCF$922
Economic Profit$497
Growth Earnings$708
13 of 23 models see the stock below the current price.
Scenario ranges
From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.
Novolog Pharm-Up 1966
Bear ILS 0.13Fair Value ILS 0.23Bull ILS 0.31
ILS 0.67 = current price (white tick)
McKesson
Bear $605Fair Value $819Bull $1,034
$870 = current price (white tick)
Compare two other stocks
Tap a field and type again, ticker or company name.
Free, no sign-up
Ranked within their sector
Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.
Novolog Pharm-Up 1966 · Health Care
Quality score43 · below median
Fair value upside-66% · bottom 25%
McKesson · Health Care
Quality score66 · Top 25%
Fair value upside-6% · above median
Bottom line
As of Aug 10, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Novolog Pharm-Up 1966 trades at ILS 0.67 versus a fair value of ILS 0.23 (-66%), while McKesson trades at $870 versus $819 (-6%).
Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.
